20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Prime Medicine, Inc. Common Stock (PRME) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 146 employees. Its market capitalization is roughly $825 million. In the fiscal year ended 2025-12-31, PRME reported $5M in revenue and ($201M) in net income.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Interactive charts & full statements → Open the PRME valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4M | $5M | $3M | $0M | $5M | $0M | $5M | — |
| Gross Profit | ($42M) | ($3M) | $3M | ($5M) | ($12M) | ($5M) | $2M | ($3M) |
| Gross Margin % | -1025.6% | -58.1% | 100.0% | — | -230.6% | — | 42.8% | — |
| Operating Income (EBIT) | ($197M) | ($208M) | ($202M) | ($205M) | ($117M) | ($84M) | ($1M) | ($2M) |
| Operating Margin % | -4824.9% | -4498.1% | -6787.4% | — | -2236.9% | — | -17.9% | — |
| Net Income | ($188M) | ($201M) | ($196M) | ($198M) | ($122M) | ($165M) | ($3M) | ($3M) |
| Net Margin % | -4613.1% | -4342.4% | -6566.6% | — | -2338.2% | — | -65.5% | — |
| EBITDA | ($180M) | ($196M) | ($190M) | ($187M) | ($121M) | ($165M) | ($1M) | ($2M) |
| Earnings Per Share (EPS) | $-1.14 | $-1.35 | $-1.65 | $-2.18 | $-1.25 | $-1.73 | $-0.04 | $-0.03 |
| Shares Outstanding (M) | 177M | 149M | 119M | 91M | 97M | 96M | 96M | 96M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $0M |
| Gross Profit | $1M | ($1M) | $1M | ($43M) | ($1M) | $1M | $2M | $0M |
| Gross Margin % | 100.0% | -116.8% | 100.0% | -3491.0% | -67.2% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($43M) | ($51M) | ($49M) | ($54M) | ($53M) | ($52M) | ($44M) | ($54M) |
| Operating Margin % | -3750.9% | -5917.5% | -5800.5% | -4406.0% | -4787.2% | -3603.3% | -2025.7% | -25948.3% |
| Net Income | ($42M) | ($49M) | ($46M) | ($51M) | ($53M) | ($52M) | ($42M) | ($53M) |
| Net Margin % | -3649.0% | -5738.6% | -5498.7% | -4129.1% | -4716.7% | -3568.8% | -1936.6% | -25128.2% |
| EBITDA | ($40M) | ($47M) | ($44M) | ($49M) | ($51M) | ($50M) | ($41M) | ($51M) |
| Earnings Per Share (EPS) | $-0.24 | $-0.28 | $-0.31 | $-0.32 | $-0.41 | $-0.40 | $-0.36 | $-0.44 |
| Shares Outstanding (M) | 177M | 177M | 149M | 161M | 129M | 131M | 119M | 120M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($156M) | ($163M) | ($123M) | ($165M) | ($132M) | ($34M) | ($6M) | ($1M) |
| Capital Expenditures (CapEx) | $1M | $5M | $7M | $9M | $16M | $4M | $1M | $1M |
| Free Cash Flow (FCF) | ($157M) | ($167M) | ($130M) | ($174M) | ($148M) | ($38M) | ($6M) | ($2M) |
| FCF Margin % | -3850.9% | -3607.4% | -4363.4% | — | -2839.2% | — | -118.7% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($41M) | ($43M) | ($37M) | ($35M) | ($41M) | ($49M) | $16M | ($26M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $2M | $2M | $2M | $1M |
| Free Cash Flow (FCF) | ($41M) | ($43M) | ($38M) | ($35M) | ($43M) | ($51M) | $14M | ($27M) |
| FCF Margin % | -3560.8% | -5014.5% | -4480.4% | -2880.5% | -3855.1% | -3526.8% | 662.1% | -13009.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $249M | $343M | $298M | $194M | $360M | $302M | $55M | $9M |
| Cash & Cash Equivalents | $47M | $63M | $182M | $42M | $188M | $185M | $37M | $9M |
| Total Liabilities | $209M | $222M | $144M | $61M | $44M | $62M | $21M | $7M |
| Total Debt (Short + Long-Term) | $9M | $8M | $4M | $9M | $12M | $7M | $18M | $0M |
| Total Shareholders' Equity | $40M | $121M | $153M | $133M | $316M | $240M | $33M | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRME viewer.
About TickerBase · Data methodology & sources · Privacy · Terms